The World's Best Long-Term Hope for Ending AIDS

The HVTN uses an integrated approach to HIV prevention to advance the fields of vaccinology, social and behavioral sciences, statistics, and immunology, as well as COVID-19 and tuberculosis (TB) vaccines.  


Study Sites

Headquartered at Fred Hutch in Seattle, the Network includes over 70 sites on four continents staffed by teams with expertise in vaccinology, immunology, and in conducting clinical trials.


Clinical Trials

For more than 20 years, the HVTN has conducted all phases of clinical trials based on the latest developments in vaccinology and immunology for the prevention of HIV, tuberculosis and COVID-19.


Scholar Awards

We are investing in the next generation of HIV prevention researchers with grants and mentoring for African American/Black and Hispanic/Latinx medical students.

HVTN Mission

Our mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally.

Who We Are

We are the world’s largest publicly-funded international collaboration focused on the evaluation of vaccines to prevent HIV/AIDS.

What We Do

Our sites conduct all phases of clinical trials — from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. 

Get Involved

Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development.

It Takes a Village

The HIV Vaccine Trials Network is an international partnership of research scientists, clinical trial sites, laboratories, statisticians, regulators and ethicists, participants, volunteers and community representatives working with industry, academia, and governments in the global search for a preventive HIV vaccine.

Recent HVTN News & Announcements

HVTN Launches First of its Kind Volunteer Registry

In recognition of National HIV Vaccine Awareness Day, May 18, the HVTN is excited to launch its Red Ribbon Registry which enables volunteers across the US to join a community of individuals ready help end HIV through the discovery of a preventive HIV vaccine.

Trial of innovative HIV vaccine using mRNA technology enrolls first participant

The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna. The study evaluates the safety of and immune responses to three different experimental vaccines against HIV.

Community Compass latest issue

Read the Latest Community Compass Issue

In this issue, we announce an award received by our very own Dr. Larry Corey, provide an update on the status of the Mosaico Study, introduce some of the former RAMP Scholars, provide an introduction to the new HVTN Faith Initiative, share activities from some of our sites and members, and a new article on community engagement and welcome new HVTN Core staff members.

News on HVTN

Read More >
HIV antibody trial results offer 'proof of concept' Outcome of AMP shows feasibility of developing potent antibody combinations to block HIV March 17, 2021
Community engagement in HIV trials guides equity for COVID-19 vaccine studies New study highlights longstanding barriers to diversity in prior decade of vaccine trials, despite federal guidelines February 19, 2021
Biostatisticians draft blueprints for COVID-19 vax trials Hutch group applies skills honed during decades of HIV prevention trials to bring about safe and effective vaccines for a new pandemic February 18, 2021
Building trust in safe and effective COVID-19 vaccines Convincing millions to get vaccinated will take more than data, facts and figures January 21, 2021

RAMP Scholar Grant

The Research and Mentorship Program (RAMP) provides structured mentorship and project funding to African American/Black and Hispanic/Latinx medical students in areas of basic, clinical behavioral, laboratory and social sciences.


 Sign up for the HVTN Newsletter

Stay up to date with the HVTN community with our HVTN newsletter to get Network announcements, HVTN programmatic updates and spotlights on our collaborators.

[* = required]